New research from Uppsala University reveals hidden inflammation in the small intestine of psoriasis patients, shedding light on their gastrointestinal symptoms and increased risk of Crohn’s disease.

Psoriasis, a chronic inflammatory skin condition, is often accompanied by systemic effects, including pro-inflammatory activity in the gut. According to Maria Lampinen, a researcher at Uppsala University, many psoriasis patients experience “leaky gut,” a condition where intestinal barrier permeability is compromised. This allows harmful substances to pass into the bloodstream, triggering systemic inflammation and potentially worsening psoriasis symptoms.
The study examined 18 psoriasis patients and 15 healthy controls, revealing elevated levels of pro-inflammatory immune cells in the intestinal samples of psoriasis patients. These immune cells were similar to those activated in skin flare-ups. Half of the psoriasis patients also displayed increased intestinal permeability, which correlated with gastrointestinal symptoms such as bloating and abdominal discomfort.
This research highlights a previously underexplored connection between skin and gut inflammation. Lampinen noted that even patients with mild psoriasis exhibited significant intestinal changes, suggesting that systemic inflammation may contribute to developing gastrointestinal diseases, including Crohn’s disease.
Implications for Psoriasis Treatment
The findings underscore the need for a holistic approach to psoriasis treatment that addresses intestinal barrier dysfunction. By targeting gut health, future therapeutic strategies may help prevent psoriasis complications and improve patient quality of life.
Note: Medical statistics provide general insights and may not account for individual variability. Always consult a healthcare professional for personalized medical advice.